Skip to main content
TipRanks
Go Ultimate75% OFF

Psyched Wellness (PSYC) AI Stock Analysis

5 Followers
TSE:PSYC

Psyched Wellness

(CNQX:PSYC)

Select Model
Rating:44Neutral
Price Target:CAD 0.01â–²(100.00% Upside)
Action:reiterated
Date:11/04/26

The score is driven primarily by weak financial performance: negative TTM gross profit, large ongoing losses, and persistent (and worsening) free cash flow burn despite revenue growth. Valuation is constrained by a negative P/E and no dividend support, while technical assessment is limited due to missing momentum/trend indicators (with only low beta indicating lower market sensitivity).

Positive Factors
Revenue GrowthRevenue growth shows that the company is gaining commercial traction and expanding sales beyond its initial base. If this trajectory continues, greater scale could improve operating leverage and provide a foundation for better economics, although profitability must still catch up.
Negative Factors
Negative Gross Profit and Large LossesNegative gross profit indicates that the current revenue base does not yet cover direct product costs, before broader operating expenses are considered. Persistently large operating and net losses weaken the path to self-funded growth and raise questions about the sustainability of the business model.

Psyched Wellness (PSYC) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:PSYC-50.00%EWC+20.47%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 1.46M
Dividend Yield
―
Average Volume (3M)
5,400
Price to Earnings (P/E)
-0.3
Beta (1Y)
0.13
Revenue Growth
115.14%
EPS Growth
-5.84%
Country
Canada
Employees
1,800
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

Psyched Wellness Business Overview & Revenue Model

Company Description

Psyched Wellness Ltd. operates as a health supplements enterprise, specializing in the production and distribution of artisanal medicinal mushrooms and their associated consumer packaged goods. A prominent offering is their Amanita Muscaria Tincture,...

Psyched Wellness Financial Statement Overview

Summary

Revenue has grown from a small base, but profitability and cash generation are very weak: TTM gross profit is negative, operating and net losses remain large relative to revenue, and both operating cash flow and free cash flow are consistently negative with worsening TTM free cash flow. Low leverage helps near-term risk, but shrinking equity and deeply negative ROE point to ongoing dilution/financing risk.

Income Statement

18Very Negative

Balance Sheet

36Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMFeb 2026Feb 2025Feb 2024Feb 2023Feb 2022
Income Statement
Total Revenue775.14K472.30K623.16K321.10K14.27K0
Gross Profit-444.19K189.79K241.89K155.71K7,5420
EBITDA-6.00M-5.08M-4.52M-3.32M-4.29M-65.31K
Net Income-5.47M-5.04M-4.26M-3.43M-4.30M-4.50M
Balance Sheet
Total Assets1.30M3.75M7.89M7.34M3.31M6.38M
Cash, Cash Equivalents and Short-Term Investments182.51K2.25M6.36M6.13M2.57M5.53M
Total Debt288.13K00000
Total Liabilities761.42K644.82K449.33K303.56K198.07K178.15K
Stockholders Equity539.26K3.10M7.44M7.03M3.11M6.20M
Cash Flow
Free Cash Flow-4.11M-4.05M-3.11M-3.11M-3.18M-3.04M
Operating Cash Flow-4.11M-4.05M-3.10M-3.03M-3.09M-3.01M
Investing Cash Flow2,5190-2,777-44.84K126.99K-28.58K
Financing Cash Flow1.08M03.39M6.64M06.51M

Psyched Wellness Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

TSE:PSYC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:JWELTSE:JWEL69NeutralCAD 1.89B24.2815.93%2.06%14.96%35.61%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TSE:PSYCTSE:PSYC44NeutralCAD 2.04M-0.31-305.94%―115.14%-5.84%
TSE:HBFGTSE:HBFG39UnderperformCAD 251.27M-12.55-311.77%―82.33%-570.45%
TSE:CULTTSE:CULT37UnderperformCAD 591.93K-0.34-9999.00%―3288.96%50.66%

* Consumer Defensive Sector Average

Performance Comparison

-75%-50%-25%0%25%TSE:PSYCTSE:JWELTSE:HBFGTSE:MOOO.XTSE:CULTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:PSYC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:PSYCPsyched Wellness Ltd0.01-0.01-50.00%
TSE:JWELJamieson Wellness45.6511.0732.03%
TSE:HBFGHappy Belly Food Group Inc1.51-0.20-11.70%
TSE:MOOO.XHappy Supplements Inc.0.35-0.15-30.00%
TSE:CULTCult Food Science Corp.0.24-0.26-52.00%

Psyched Wellness Corporate Events

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Psyched Wellness Secures Related-Party Term Loan to Fund AMA Brand Operations

Positive
Oct 8, 2026

Psyched Wellness has secured a US$110,577 term loan from Gotham Green funds, which will be used to fund operating expenses and inventory purchases tied to its AMA-branded Amanita Muscaria products. The loan, bearing interest at SOFR plus 5% and matur...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Psyched Wellness Secures Insider-Backed Term Loan to Fund AMA Brand Growth

Positive
Aug 5, 2026

Psyched Wellness has secured US$230,000 in term notes from Gotham Green Fund III entities to fund operating expenses and inventory purchases tied to its AMA-branded mushroom-derived wellness products. The notes bear interest at SOFR plus 5% and are s...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026